特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:前立腺がんの疫学的予測

Prostate Cancer: Epidemiology Forecast to 2028

発行 GlobalData 商品コード 331730
出版日 ページ情報 英文 48 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.84円で換算しております。
EpiCast Report:前立腺がんの疫学的予測 Prostate Cancer: Epidemiology Forecast to 2028
出版日: 2019年08月31日 ページ情報: 英文 48 Pages
概要

当レポートでは、世界の主要8ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国、日本、中国) における前立腺がんの発症状況と今後の見通しについて分析し、疾患の特徴や、現在の有病者の発症状況、今後10年間の有病件数の予測値などを調査しております。

第1章 目次

第2章 前立腺がん:エグゼクティブ・サマリー

  • 関連分析
  • 刊行予定の関連分析

第3章 疫学的予測

  • 疾患の背景事情
  • リスク要因と共存症
  • 過去の世界的な傾向
  • 予測手法
    • 利用した情報源
    • 予測の前提条件と手法
  • 前立腺がんの疫学的予測
    • 診断済みの有病者数
    • 診断済みの有病者数:年齢別
    • 診断済みの有病者数:グリソンスコア (悪性度) 別
    • 診断済みの有病者数:診断時の病期別
    • 診断済みの有病者数:リスクのカテゴリー別
    • 診断時の転移件数
    • 術後5年後の診断済み有病者数
    • 術後5年後の診断済み有病者数:ホルモン感受性疾患から去勢抵抗性前立腺がん (PRPC) への転移件数、状態別
  • 議論
    • 疫学的予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

List of Tables

  • Table 1: Risk Factors and Comorbidities for Prostate Cancer
  • Table 2: AJCC Staging of Prostate Cancer
  • Table 3: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country and Specialty

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of Prostate Cancer, Ages ≥30 Years, Men, N, 2018 and 2028
  • Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of Prostate Cancer, Ages ≥30 Years, Men, N, 2018 and 2028
  • Figure 3: 8MM, Diagnosed Incidence of Prostate Cancer, Men, Ages ≥30 Years, 2008-2028
  • Figure 4: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer
  • Figure 5: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer by Gleason Scores
  • Figure 6: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis
  • Figure 7: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer by Risk Category
  • Figure 8: 8MM, Sources Used, Metastatic Cases at Diagnosis
  • Figure 9: 8MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Prostate Cancer
  • Figure 10: 8MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Prostate Cancer by Progression from Hormone-Sensitive Disease to CRPC
  • Figure 11: 8MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Prostate Cancer by Progression from Hormone-Sensitive Disease to CRPC by Status
  • Figure 12: 8MM, Diagnosed Incident Cases of Prostate Cancer, Ages ≥30 Years, Men, N, 2018
  • Figure 13: 8MM, Age-Specific Diagnosed Incident Cases of Prostate Cancer, Men, N, 2018
  • Figure 14: 8MM, Diagnosed Incident Cases of Prostate Cancer by Gleason Score, Ages ≥30 Years, Men, N, 2018
  • Figure 15: 8MM, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis, Ages ≥30 Years, Men, N, 2018
  • Figure 16: 8MM, Diagnosed Incident Cases of Prostate Cancer by Risk Category, Ages ≥30 Years, Men, N, 2018
  • Figure 17: 8MM, Metastatic Cases at Diagnosis, Ages ≥30 Years, Men, N, 2018
  • Figure 18: 8MM, Five-Year Diagnosed Prevalent Cases of Prostate Cancer, Ages ≥30 Years, Men, N, 2018
  • Figure 19: 8MM, Diagnosed Five-Year Prevalent Cases of Prostate Cancer that Progress from Hormone-Sensitive Disease to CRPC by Status, Ages ≥30 Years, Men, N, 2018
目次
Product Code: GDHCER215-19

Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.2 million men were diagnosed with prostate cancer in 2018 (International Agency for Research on Cancer, 2019). Almost all prostate cancers are adenocarcinomas, a type of cancer that develops in gland cells. Most prostate cancers are asymptomatic and grow very slowly. In advanced stages of prostate cancer, the malignancy has spread to other organs such as seminal vesicles, lymph nodes, or bones. When a tumor fails to respond to androgen deprivation therapy, it is referred to as castration-resistant prostate cancer (CRPC) (National Cancer Institute, 2019a). Changes in PSA testing and screening guidelines since 2007 have led to substantial changes in prostate cancer incidence. GlobalData epidemiologists used the most recent data for incidence calculations in the 8MM.

In 2018, the US accounted for 30.46% of the diagnosed incident cases of prostate cancer in the 8MM, with 170,744 cases. There were 216,980 cases in the 5EU in 2018, or 38.71% of the diagnosed incident cases, while Japan had 93,916 diagnosed incident cases and China had 78,874 diagnosed incident cases. In the 8MM, the number of diagnosed incident cases of prostate cancer will grow by 19.41% over the forecast period at an Annual Growth Rate (AGR) of 1.94% from 560,514 cases in 2018 to 669,284 cases by 2028. Of the 8MM, the US is expected to have the highest number of diagnosed incident cases, increasing from 170,744 cases in 2018 to 204,127 cases in 2028. Italy had the lowest number of diagnosed incident cases of prostate cancer in 2018, at 35,300 cases. Any change in the diagnosed incident cases of prostate cancer in the 8MM is attributable to changing population demographics in the respective markets.

Scope

  • The Prostate Cancer Epidemiology Report and Model provide an overview of the risk factors and global trends of prostate cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
  • This report includes 10-year epidemiological forecast for diagnosed incident cases of prostate cancer in men segmented by age (beginning at 30 years), Gleason scores (2-10), stage at diagnosis (stage I, II, III, IV-M0, and IV-M1), risk category (very low/low risk, intermediate risk, and high/very high risk), and metastatic cases at diagnosis (bone metastases only and bone metastases with visceral metastases) in these markets. Additionally, this report forecasts five-year diagnosed prevalent cases of prostate cancer segmented by castration resistance and metastases.
  • The prostate cancer epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The Prostate Cancer Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
  • Quantify patient populations in the global prostate cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for prostate cancer therapeutics in each of the markets covered.
  • Understand magnitude of prostate cancer by stage at diagnosis and risk category.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Prostate Cancer: Executive Summary

  • 2.1 Related Reports
  • 2.2 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods, Population
    • 3.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer
    • 3.4.4 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Gleason Scores
    • 3.4.5 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis
    • 3.4.6 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Risk Category
    • 3.4.7 Forecast Assumptions and Methods, Metastatic Cases at Diagnosis
    • 3.4.8 Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases of Prostate Cancer
    • 3.4.9 Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases (Metastatic and Non-Metastatic) that Progress from Hormone-Sensitive Disease to CRPC by Status
  • 3.5 Epidemiological Forecast for Prostate Cancer (2018-2028)
    • 3.5.1 Diagnosed Incident Cases of Prostate Cancer
    • 3.5.2 Age-Specific Incident Cases of Prostate Cancer
    • 3.5.3 Diagnosed Incident Cases of Prostate Cancer by Gleason Score
    • 3.5.4 Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis
    • 3.5.5 Diagnosed Incident Cases of Prostate Cancer by Risk Category
    • 3.5.6 Metastatic Cases at Diagnosis
    • 3.5.7 Five-Year Diagnosed Prevalent Cases of Prostate Cancer
    • 3.5.8 Diagnosed Five-Year Prevalent Cases of Prostate Cancer that Progress from Hormone-Sensitive Disease to CRPC by Status
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of Analysis
    • 3.6.3 Strengths of Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 Primary Market Research - Prescriber Survey
  • 4.3 Abbreviations
  • 4.4 About the Authors
    • 4.4.1 Epidemiologist
    • 4.4.2 Reviewers
    • 4.4.3 Global Director of Therapy Analysis and Epidemiology
    • 4.4.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.5 About GlobalData
  • 4.6 Contact Us
  • 4.7 Disclaimer